Diamedica TherapeuticsDMAC
13F holders, Q1 2024 (March 31)32holders
2famous investors
$2.77avg. 13F price*
At the end of Q1 2024, 32 institutions reported holding Diamedica Therapeutics Inc. (DMAC) in their 13F filings. The largest holders were Vanguard Group Inc. ($2.8M), Omega Advisors (Leon Cooperman) ($2.4M) and First Manhattan Co. Llc. ($2.4M). 2 famous investors held it, including Leon Cooperman (0.1% of Omega Advisors (Leon Cooperman)'s portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Diamedica Therapeutics Inc.
- CUSIP
- 25253X207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $5K |
| Exits | 7 | $951K |
Ownership 32 holders
| Vanguard Group Inc. | 0.00% | Add +26.4% | 1,013,522 | $2.8M |
| Omega Advisors (Leon Cooperman) | 0.10% | No change | 883,623 | $2.4M |
| First Manhattan Co. Llc. | 0.01% | Add +640.8% | 850,038 | $2.4M |
| Paragon Associates & Paragon Associates II Joint Venture | 2.47% | No change | 500,000 | $1.4M |
| Geode Capital Management, LLC | 0.00% | Add +9.3% | 239,235 | $663K |
| Bleichroeder LP | 0.15% | No change | 222,317 | $616K |
| Susquehanna International Group, LLP | 0.00% | Add +657.9% | 209,332 | $580K |
| Northern Trust Corp. | 0.00% | Reduce -4.3% | 127,819 | $354K |
| Aristides Capital LLC | 0.13% | No change | 106,333 | $295K |
| BlackRock Inc. | 0.00% | Reduce -1.3% | 103,370 | $286K |
| Morgan Stanley | 0.00% | Reduce -24.3% | 91,573 | $254K |
| State Street Corp. | 0.00% | No change | 66,629 | $185K |
| Catalyst Financial Partners LLC | 0.02% | No change | 36,267 | $94K |
| Citadel Advisors | 0.00% | Add +5.8% | 24,020 | $67K |
| Bank of New York Mellon Corp | 0.00% | Reduce -29.9% | 24,000 | $66K |
| Stonebridge Capital Advisors LLC | 0.01% | No change | 20,000 | $55K |
| Dimensional Fund Advisors LP | 0.00% | No change | 16,959 | $47K |
| Jane Street Group, LLC | 0.00% | Reduce -35.9% | 15,238 | $42K |
| BNP Paribas Financial Markets | 0.00% | Add +3.6% | 14,500 | $40K |
| Charles Schwab Investment Management Inc. | 0.00% | No change | 13,251 | $37K |
| MassMutual Private Wealth & Trust, FSB | 0.00% | No change | 4,824 | $13K |
| US Bancorp \de | 0.00% | No change | 4,335 | $12K |
| Naples Money Management LLC | 0.01% | Reduce -23.2% | 2,978 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -62.9% | 2,696 | $7K |
| UBS Group AG | 0.00% | New | 1,926 | $5K |
| TD Waterhouse Canada Inc. | 0.00% | No change | 1,070 | $4K |
| Legend Financial Advisors, Inc. | 0.00% | No change | 1,000 | $3K |
| Osaic Holdings, Inc. | 0.00% | No change | 1,000 | $3K |
| Royal Bank of Canada | 0.00% | Reduce -21.9% | 845 | $2K |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 230 | $637 |
| Wells Fargo & Company | 0.00% | Add +1.7% | 175 | $485 |
| Toronto Dominion Bank | 0.00% | No change | 24 | $66 |
"% of holder's portfolio" is DMAC's weight in each manager's 13F, not the share of Diamedica Therapeutics Inc. the manager owns.